Entasis Therapeutics Holdings Inc. logo

ETTX

Entasis Therapeutics Holdings Inc. · NASDAQ

Website

Entasis Therapeutics Holdings Inc. (ETTX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for ETTX in the last 30 days. The most recent was published Oct 12, 2022.

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.

Latest news

25 items

ETTX FAQ

8 questions
  • What does Entasis Therapeutics Holdings Inc. do?
    Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated...
  • What is the latest news on ETTX?
    Quantisnow has not tracked any new filings, ratings or press releases for ETTX in the last 30 days. The most recent wire item was published on October 12, 2022.
  • Where does ETTX stock trade?
    Entasis Therapeutics Holdings Inc. (ETTX) is listed on NASDAQ.
  • What sector and industry is ETTX in?
    Entasis Therapeutics Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Entasis Therapeutics Holdings Inc. go public?
    Entasis Therapeutics Holdings Inc. (ETTX) completed its IPO in 2018.
  • What are analysts saying about ETTX?
    Across the last 4 analyst actions on Entasis Therapeutics Holdings Inc., there were 0 upgrades and 2 downgrades. The most recent action was from Wedbush: Neutral with a $1.80 price target on 2022-03-08. Recent price targets range from $1.80 to $7.00.
  • What companies are similar to ETTX?
    Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), ABT (Abbott Laboratories). Compare ETTX side-by-side with any of them on Quantisnow.
  • How can I track ETTX on Quantisnow?
    Quantisnow aggregates Entasis Therapeutics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ETTX to receive live email and push alerts on every new disclosure.